Browse > Article
http://dx.doi.org/10.3345/kjp.2011.54.9.380

Short term outcomes of topiramate monotherapy as a first-line treatment in newly diagnosed West syndrome  

Lee, Gyu-Min (Department of Pediatrics, Kyung Hee University School of Medicine)
Lee, Kyung-Suk (Department of Pediatrics, Kyung Hee University School of Medicine)
Lee, Eun-Hye (Department of Pediatrics, Kyung Hee University School of Medicine)
Chung, Sa-Jun (Department of Pediatrics, Kyung Hee University School of Medicine)
Publication Information
Clinical and Experimental Pediatrics / v.54, no.9, 2011 , pp. 380-384 More about this Journal
Abstract
Purpose: To investigate the efficacy of topiramate monotherapy in West syndrome prospectively. Methods: The study population included 28 patients (15 male and 13 female children aged 2 to 18 months) diagnosed with West syndrome. After a 2-week baseline period for documentation of the frequency of spasms, topiramate was initiated at 2 mg/kg/day. The dose was increased by 2 mg/kg every week to a maximum of 12 mg/kg/day. Clinical assessment was based on the parents' report and a neurological examination every 2 weeks for the first 2 months of treatment. The baseline electroencephalograms (EEGs) were compared with the post-treatment EEGs at 2 weeks and 1 month. Results: West syndrome was considered to be cryptogenic in 7 of the 28 patients and symptomatic in 21 patients. After treatment, 11 patients (39%) became spasm-free, 6 (21%) had more than 50% spasms-reduction, 3 (11%) showed less than 50% reduction, and 8 (29%) did not respond. The effective daily dose for achieving more than 50% reduction in spasm frequency, including becoming spasm-free, was found to be $5.8{\pm}1.1$ mg/kg/day. Nine patients (32%) showed complete disappearance of spasms and hypsarrhythmia, and 11 (39%) showed improved EEG results. Despite adverse events (4 instances of irritability, 3 of drowsiness, and 1 of decreased feeding), no patients discontinued the medication. Conclusion: Topiramate monotherapy seems to be effective and well tolerated as a first line therapy for West syndrome and is not associated with serious adverse effects.
Keywords
West syndrome; Topiramate; Monotherapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Langtry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997;54:752-73.   DOI   ScienceOn
2 Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol 2000;15 Suppl 1:S22-6.
3 Sen HA, O'Halloran HS, Lee WB. Case reports and small case series: topiramate-induced acute myopia and retinal striae. Arch Ophthalmol 2001;119:775-7.
4 Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37 Suppl 2:S18-22.
5 Juhasz C, Chugani HT, Muzik O, Chugani DC. Neuroradiological assessment of brain structure and function and its implication in the pathogenesis of West syndrome. Brain Dev 2001;23:488-95.   DOI   ScienceOn
6 Satoh J, Mizutani T, Morimatsu Y. Neuropathology of the brainstem in age-dependent epileptic encephalopathy--especially of cases with infantile spasms. Brain Dev 1986;8:443-9.   DOI   ScienceOn
7 Baram TZ, Mitchell WG, Hanson RA, Snead OC 3rd, Horton EJ. Cerebrospinal fluid corticotropin and cortisol are reduced in infantile spasms. Pediatr Neurol 1995;13:108-10.   DOI   ScienceOn
8 Baram TZ, Schultz L. Corticotropin-releasing hormone is a rapid and potent convulsant in the infant rat. Brain Res Dev Brain Res 1991;61:97-101.   DOI   ScienceOn
9 Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004;62:1668-81.   DOI   ScienceOn
10 Yanagaki S, Oguni H, Hayashi K, Imai K, Funatuka M, Tanaka T, et al. A comparative study of high-dose and low-dose ACTH therapy for West syndrome. Brain Dev 1999;21:461-7.   DOI   ScienceOn
11 Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996;97:375-9.
12 Bobele GB, Ward KE, Bodensteiner JB. Hypertrophic cardiomyopathy during corticotropin therapy for infantile spasms. A clinical and echocardiographic study. Am J Dis Child 1993;147:223-5.   DOI
13 Shamir R, Garty BZ. Pneumocystis carinii pneumonia associated with adrenocorticotropic hormone treatment for infantile spasms. Eur J Pediatr 1992;151:867.
14 Lee IK, Kim SK, Lee R, Kwon YS, Lee JH, Chae JH, et al. Efficacy of topiramate in West syndrome. J Korean Epilepsy Soc 2000;4:27-9.
15 Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;52:1330-7.   DOI   ScienceOn
16 Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology 1999;52:1338-44.   DOI   ScienceOn
17 Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;52:1882-7.   DOI
18 Hsieh MY, Lin KL, Wang HS, Chou ML, Hung PC, Chang MY. Low-dose topiramate is effective in the treatment of infantile spasms. Chang Gung Med J 2006;29:291-6.
19 Korinthenberg R, Schreiner A. Topiramate in children with west syndrome: a retrospective multicenter evaluation of 100 patients. J Child Neurol 2007;22:302-6.   DOI   ScienceOn
20 Albsoul-Younes AM, Salem HA, Ajlouni SF, Al-Safi SA. Topiramate slow dose titration: improved efficacy and tolerability. Pediatr Neurol 2004;31:349-52.   DOI   ScienceOn
21 Peltzer B, Alonso WD, Porter BE. Topiramate and adrenocorticotropic hormone (ACTH) as initial treatment for infantile spasms. J Child Neurol 2009;24:400-5.   DOI   ScienceOn
22 Appleton RE. Vigabatrin in the management of generalized seizures in children. Seizure 1995;4:45-8.   DOI   ScienceOn
23 Suzuki Y, Nagai T, Ono J, Imai K, Otani K, Tagawa T, et al. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 1997;38:1035-8.   DOI   ScienceOn
24 Karvelas G, Lortie A, Scantlebury MH, Duy PT, Cossette P, Carmant L. A retrospective study on aetiology based outcome of infantile spasms. Seizure 2009;18:197-201.   DOI   ScienceOn
25 Ben-Zeev B, Watemberg N, Augarten A, Brand N, Yahav Y, Efrati O, et al. Oligohydrosis and hyperthermia: pilot study of a novel topiramate adverse effect. J Child Neurol 2003;18:254-7.   DOI   ScienceOn
26 Kossoff EH, Pyzik PL, Furth SL, Hladky HD, Freeman JM, Vining EP. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia 2002;43:1168-71.   DOI   ScienceOn
27 Riikonen R, Simell O, Jaaskelainen J, Rapola J, Perheentupa J. Disturbed calcium and phosphate homeostasis during treatment with ACTH of infantile spasms. Arch Dis Child 1986;61:671-6.   DOI   ScienceOn
28 Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999;40:1627-33.   DOI   ScienceOn
29 Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990;42:223-86.
30 Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 1997;38: 1270-4.   DOI   ScienceOn
31 Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998;39:1324-8.   DOI   ScienceOn
32 Glauser TA, Miles MV, Tang P, Clark P, McGee K, Doose DR. Topiramate pharmacokinetics in infants. Epilepsia 1999;40:788-91.   DOI   ScienceOn
33 Mikaeloff Y, de Saint-Martin A, Mancini J, Peudenier S, Pedespan JM, Vallee L, et al. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003;53:225-32.   DOI   ScienceOn
34 Zou LP, Ding CH, Fang F, Sin NC, Mix E. Prospective study of first-choice topiramate therapy in newly diagnosed infantile spasms. Clin Neuropharmacol 2006;29:343-9.   DOI   ScienceOn
35 Kwon YS, Jun YH, Hong YJ, Son BK. Topiramate monotherapy in infantile spasm. Yonsei Med J 2006;47:498-504.   DOI   ScienceOn
36 Ben-Menachem E, Sander JW, Stefan H, Schwalen S, Schauble B. Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy. Clin Ther 2008;30:1180-95.   DOI   ScienceOn
37 Sorel L, Dusaucy-Bauloye A. Findings in 21 cases of Gibbs' hypsarrhythmia; spectacular effectiveness of ACTH. Acta Neurol Psychiatr Belg 1958;58:130-41.
38 Bobele GB, Bodensteiner JB. The treatment of infantile spasms by child neurologists. J Child Neurol 1994;9:432-5.   DOI   ScienceOn
39 Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43.   DOI   ScienceOn